drugset / Trial / NCT02649270
Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The humanized recombinant anti-CD6 monoclonal antibody Injection (T1h) has been approved for psoriasis in India. The first trial in China is to evaluate the tolerability, safety, pharmacodynamic, pharmacokinetics and preliminary efficacy of T1h for patients with psoriasis.
Timeline
- Start
- 2014-10
- Primary completion
- 2015-06
- Completion
- 2017-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itolizumab | Monoclonal antibody | 0.2 mg/kg | Intravenous |
| Subject | Itolizumab | Monoclonal antibody | 0.4 mg/kg | Intravenous |
| Subject | Itolizumab | Monoclonal antibody | 0.8 mg/kg | Intravenous |
| Subject | Itolizumab | Monoclonal antibody | 1.6 mg/kg | Intravenous |